Advanced search
Publication Cover
Current Medical Research and Opinion Volume 33, 2017 - Issue 12
Submit an article Journal homepage
662
Views
12
CrossRef citations to date
0
Altmetric
Musculoskeletal

Relapse outcomes, safety, and treatment patterns in patients diagnosed with relapsing-remitting multiple sclerosis and initiated on subcutaneous interferon β-1a or dimethyl fumarate: a real-world study

Frank R. ErnstHealth Economics and Outcomes Research, Indegene, Inc., Kennesaw, GA, USA;
,
Peri BarrHealth Economics and Outcomes Research, Indegene, Inc., Kennesaw, GA, USA;
,
Riad ElmorHealth Economics and Outcomes Research, Indegene, Inc., Kennesaw, GA, USA;
&
Schiffon L. WongGlobal Evidence & Value Development, Global Research & Development, EMD Serono, Inc., Billerica, MA, USACorrespondence[email protected]
Pages 2099-2106 | Received 07 Jun 2017, Accepted 06 Sep 2017, Published online: 28 Sep 2017

Citations (12)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Ana Rodríguez-Regal, Laura Ramos-Rúa, Luis Anibarro-García, Ana María Lopez Real & María del Campo Amigo-Jorrín. (2021) Effectiveness of Dimethyl Fumarate in Real-World Clinical Practice and Strategy to Minimize Adverse Effects and Use of Healthcare Resources. Patient Preference and Adherence 15, pages 149-158.
Read now

Articles from other publishers (11)

Mark S. Freedman, Patricia K. Coyle, Kerstin Hellwig, Barry Singer, Daniel Wynn, Bianca Weinstock-Guttman, Silva Markovic-Plese, Andrew Galazka, Fernando Dangond, Julie Korich & Anthony T. Reder. (2024) Twenty Years of Subcutaneous Interferon-Beta-1a for Multiple Sclerosis: Contemporary Perspectives. Neurology and Therapy 13:2, pages 283-322.
Crossref
Vahid Shaygannejad, Omid Mirmosayyeb, Sara Bagherieh, Parisa Shaygan & Mahsa Ghajarzadeh. (2023) The Efficacy of Fingolimod and Interferons in Controlling Disability and Relapse Rate in Patients with Multiple Sclerosis: A Systematic Review and Meta-Analysis. International Journal of Preventive Medicine 14.
Crossref
Malte Roar, Amalie Rhode Høgh Nielsen, Jonas Munksgaard Berg, Georgi Sirakov, Morten Stilund, Jakob Schäfer, Rikke Ratzer, Jette Frederiksen, Nasrin Asgari, Said Nasim Ashna, Henrik Boye Jensen, Matthias Kant, Ásta Theódorsdóttir, Zsolt Illes, Finn Sellebjerg, Melinda Magyari, Louise Mose Schlosser, Hilde Nordborg, Stig Wergeland & Tobias Sejbaek. (2023) Discontinuation of dimethyl fumarate in multiple sclerosis - a nationwide study. Multiple Sclerosis and Related Disorders 80, pages 105127.
Crossref
Marissa Betts, Kyle Fahrbach, Binod Neupane, Mahmoud Slim, Maria Pia Sormani, Gary Cutter, Thomas PA Debray & Marvin Rock. (2023) Handling related publications reporting real-world evidence in network meta-analysis: a case study in multiple sclerosis. Journal of Comparative Effectiveness Research 12:8.
Crossref
Joshua MardanMohammad Akhtar HussainMichelle AllanLisa B Grech. (2021) Objective medication adherence and persistence in people with multiple sclerosis: a systematic review, meta-analysis, and meta-regression. Journal of Managed Care & Specialty Pharmacy 27:9, pages 1273-1295.
Crossref
David M. Kern & M. Soledad Cepeda. (2020) Treatment patterns and comorbid burden of patients newly diagnosed with multiple sclerosis in the United States. BMC Neurology 20:1.
Crossref
Jacqueline A. Nicholas, Natalie C. Edwards, Roger A. Edwards, Anna Dellarole, Megan Grosso & Amy L. Phillips. (2020) Real-world adherence to, and persistence with, once- and twice-daily oral disease-modifying drugs in patients with multiple sclerosis: a systematic review and meta-analysis. BMC Neurology 20:1.
Crossref
Geoffrey Liang, Julia Chai, Huah Shin Ng & Helen Tremlett. (2020) Safety of dimethyl fumarate for multiple sclerosis: A systematic review and meta-analysis. Multiple Sclerosis and Related Disorders 46, pages 102566.
Crossref
Juan Ignacio Rojas, Agustín Pappolla, Liliana Patrucco, Edgardo Cristiano & Francisco Sánchez. (2020) Do clinical trials for new disease modifying treatments include real world patients with multiple sclerosis?. Multiple Sclerosis and Related Disorders 39, pages 101931.
Crossref
Majid Gasim, Charles N. Bernstein, Lesley A. Graff, Scott B. Patten, Renee El-Gabalawy, Jitender Sareen, James M. Bolton, James J Marriott, John D. Fisk & R.A. Marrie. (2018) Adverse psychiatric effects of disease-modifying therapies in multiple Sclerosis: A systematic review. Multiple Sclerosis and Related Disorders 26, pages 124-156.
Crossref
James D Bowen, Chris M Kozma, Megan M Grosso & Amy L Phillips. (2018) A real-world comparison of relapse rates, healthcare costs and resource use among patients with multiple sclerosis newly initiating subcutaneous interferon beta-1a versus oral disease-modifying drugs. Multiple Sclerosis Journal - Experimental, Translational and Clinical 4:4, pages 205521731881903.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.